Charity number: 1123760 Company number: 6078396 (England and Wales) British Society for Histocompatibility and Immunogenetics Report of the Trustees and Unaudited Financial Statements For the year ended 31 December 2024 British Society for Histocompatibility and Immunogenetics Contents Page For the year ended 31 December 2024 |Report of the Trustees|1 to 4| |---|---| |Independent Examiner's Report to the Trustees|5| |Statement of Financial Activities|6| |Statement of Financial Position|7| |Notes to the Financial Statements|8 to 13| |Detailed Statement of Financial Activities|14 to 15| ## British Society for Histocompatibility and Immunogenetics Report of the Trustees ## For the year ended 31 December 2024 The Trustees, who are also directors for the purposes of company law, have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2024. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019). ## **OBJECTIVES AND ACTIVITIES** The objects of the Society, as stated in its Memorandum of Association, are; To promote and protect health for the public benefit in particular by: (a) developing and maintaining good practice in Histocompatibility and Immunogenetics by ensuring the highest professional standards of competence; (b) encouraging the advancement of scientific research and knowledge and of its application in all aspects of Histocompatibility and Immunogenetics and disseminating the useful results thereof. The main activities of the society that contribute to the achievement of the objectives are; Annual Conference BSHI Annual Conference was held in person in 2024.The meeting provided an educational programme of lectures and seminars, including plenary lectures provided by world experts in the field of histocompatibility and Immunogenetics. Sessions were also held for BSHI Members to present short talks and case studies. Two awards sessions were held. One for best abstract and one session for the Next Generation Scientist. ## **Objectives and aims** The trustees have considered the Charity Commission's guidance on public benefit, including the guidance 'public benefit: running a charity (PB2)'. 1 of 15 ## British Society for Histocompatibility and Immunogenetics Report of the Trustees Continued ## For the year ended 31 December 2024 ## **ACHIEVEMENTS AND PERFORMANCE** Diploma and other training courses BSHI supplies and administers a Diploma in Histocompatibility and Immunogenetics, to facilitate specialist learning in the field. Graduating diplomats received their awards at the Annual Conference. A successful series of one and two day training courses were held to support BSHI Diploma, Trainee Clinical Scientists, Biomedical Scientists and those undertaking higher qualifications. BSHI ran a higher training meeting for members considering taking the FRC Path examinations. BSHI also administers a CPD scheme for the membership. ## Special Interest Groups The special interest groups were all busy this year providing educational workshops and forums for discussion between the different laboratories. The 3 active SIGs are the Antibody SIG, the Next Generation Sequencing SIG and the Haematopoietic Stem Cell SIG with meetings held this year around platelets and transplanting highly sensitised patients. ## Bursaries and Grants BSHI supplied bursaries to its members to attend scientific and educational meetings. These included the European Federation of Immunogenetics and British Society for Histocompatibility and Immunogenetics meetings. The society also awarded the Julia Bodmer Travel Award, which allows a junior member of the society the opportunity to visit another laboratory to bring back some research ideas or new technology to their own laboratory. The recipient of the award presents their findings at the BSHI annual conference. ## Representation to other professional bodies The BSHI has nominated representatives to a number of other professional organisations and these representatives link to the BSHI Committee through the Professional Advisory Group. Elected members of BPAG are responsible for co-ordinating BSHI input to official working groups and documents. BSHI is represented at the Association of Clinical Scientists, Clinical Pathology Accreditation UK Ltd, the Federation of Healthcare Science, the National External Quality Assurance Advisory Panel for Immunology, and the Royal College of Pathologists and NHSBT-ODT advisor groups. Establishment and maintenance of appropriate standards within H & I is addressed through the BPAG. BPAG will interact with other professional organisations e.g. European Federation for Immunogenetics, British Transplantation Society as required and set up Standards Working Groups to address specific topics. ## Online Virtual Conference Facility BSHI provides virtual conference infrastructure via Microsoft Teams, enabling remote conferencing and education to take place and at the same time reducing waste and carbon impact. ## Online Scientific Journals BSHI continues to supply access to scientific literature that members do not readily have access to. ## Publications BSHI publishes a quarterly newsletter which is sent to all of the memberships. This contains reports from meetings, CPD journal based learning exercises and updates on developments within the society. ## Online CPD Scheme BSHI provides and manages online Continuing Professional Development, (CPD) scheme for its members via CPDMe. 2 of 15 British Society for Histocompatibility and Immunogenetics Report of the Trustees Continued ## For the year ended 31 December 2024 ## **FINANCIAL REVIEW** ## **Reserves** The overall reserves of the charity have again increased to £121,509 which leaves the charity in a strong position to continue to pursue its objectives for the foreseeable future. ## **Going concern** The trustees are confident that BSHI will be able to continue and pursue its objectives for the foreseeable future. ## **REFERENCE AND ADMINISTRATIVE INFORMATION** **Name of Charity** British Society for Histocompatibility and Immunogenetics **Charity registration number** 1123760 **Company registration number** 6078396 **Principal address** C/O Executive Business Support Ltd City Wharf Davidson Road Lichfield Staffs WS14 9DZ ## **Trustees** The trustees and officers serving during the year and since the year end were as follows: Richard Battle Daniel Eggleston Corinna Freeman Helena Lee Jessie Martin Sarah Peacock Emily Ryan Olivia Shaw Carla Rosser (Appointed: 23 August 2024) Rachel Smith (Resigned: 31 January 2024) Sarah Maxfield (Appointed: 23 August 2024) Rebecca McGuire (Appointed: 02 February 2024) Raymond Fernando (Appointed: 02 February 2024) **Secretary** Carla Rosser **Independent examiner** Marie Hartwell VESEY Accounting Services Ltd Suite 1, Trinity House 33a Market Street Lichfield, Staffs WS13 6LA 3 of 15 British Society for Histocompatibility and Immunogenetics Report of the Trustees Continued For the year ended 31 December 2024 ## **Bankers** Barclays Bank Plc Witham Business Centre 59 Newland Street Witham Essex CM8 2AJ Approved by the Board of Trustees and signed on its behalf by 10 September 2025 Corinna Freeman............................................................................. 4 of 15 ## British Society for Histocompatibility and Immunogenetics Independent Examiners Report to the Trustees ## For the year ended 31 December 2024 I report to the trustees on my examination of the accounts of the charitable company for the year ended 31 December 2024. ## **Responsibilities and basis of report** As the charity Trustees, who are also directors for the purposes of company law, are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act'). Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act. ## **Independent examiners qualified statement** I confirm that no other matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or 4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). I confirm that there are no other matters to which your attention should be drawn to enable a proper understanding of the accounts to be reached. Marie Hartwell VESEY Accounting Services Ltd Suite 1, Trinity House 33a Market Street Lichfield, Staffs WS13 6LA 10 September 2025 5 of 15 ## British Society for Histocompatibility and Immunogenetics Statement of Financial Activities (including Income and Expenditure Account) For the year ended 31 December 2024 |**Notes**
**Income and endowments from:**
Charitable activities
3
Other trading activities
4
Investments
5
**Total**
**Expenditure on:**
Charitable activities
6/7
**Total**
**Net income**
**Reconciliation of funds**
Total funds brought forward
**Total funds carried forward**|**Unrestricted**
**funds**
**£**
102,368
-
1,385|**2023**
**£**
80,889
(426)
1,066| |---|---|---| ||**103,753**|**81,529**| ||(81,541)|(72,615)| ||**(81,541)**|**(72,615)**| ||**22,212**
99,297|**8,914**
90,383| ||**121,509**|**99,297**| 6 of 15 6078396 Registered Number : ## British Society for Histocompatibility and Immunogenetics Statement of Financial Position As at 31 December 2024 |**Notes**
**Fixed assets**
Tangible assets
14
**Current assets**
15
Debtors
Cash at bank and in hand
**Creditors: amounts falling due within one year**
16
**Net current assets**
**Total assets less current liabilities**
**Net assets**
**The funds of the charity**
Unrestricted income funds
17
**Total funds**|**£**
**2024**
-|**£**
**2023**
29| |---|---|---| ||**-**|**29**| ||29,305
105,047|19,380
88,658| ||**134,352**|**108,038**| ||(12,843)
**121,509**|(8,770)
**99,268**| ||**121,509**|**99,297**| |||| ||**121,509**|**99,297**| ||121,509|99,297| ||**121,509**|**99,297**| For the year ended 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476, The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies’ regime. The financial statements were approved and authorised for issue by the Board and signed on its behalf by: Corinna Freeman Trustee 10 September 2025 7 of 15 ## British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements For the year ended 31 December 2024 ## **1. Accounting Policies** ## **Basis of accounting** The financial statements have been prepared under the historical cost convention, except for investments which are included at market value and the revaluation of certain fixed assets and in accordance with the Charities SORP (FRS 102) ‘Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)’, Financial Reporting Standard 102 the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), and the Companies Act 2006. British Society for Histocompatibility and Immunogenetics meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s). ## **Going concern** During 2024 BSHI was able to continue with its objectives with another successful year of member subscriptions, and the ability to hold the in person annual conference helped to improve income during the year. BSHI continues to seek cost effective ways of supporting their membership and the trustees are confident that BSHI will be able to continue and pursue its objectives for the immediate foreseeable future. ## **Incoming resources** All incoming resources are included in the statement of financial activities when the Charity is entitled to the income, and the amount can be quantified with reasonable accuracy. The following specific policies are applied to particular categories of income: Income from investments is included in the year in which it is receivable. ## **Resources expended** Liabilities are recognised as resources expended when there is a legal or constructive obligation committing the Charity to the expenditure: ## **Tangible fixed assets** Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis: Plant and machinery Computer equipment Motor vehicles Fixtures and fittings 25% Reducing balance 25% Reducing balance 25% Reducing balance 25% Reducing balance 8 of 15 ## British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued For the year ended 31 December 2024 ## **3. Income from charitable activities** |**Unrestricted funds**
_Charitable activities_
Advertising
Subscriptions
Conference
Qualifications
_Other member activities_
Other member activities
Income from charitable activities|**2024**
**£**
18,500
27,030
3,243
43,735|**2023**
**£**
17,850
26,080
2,800
24,045| |---|---|---| ||**92,508**
225
9,635|**70,775**
-
10,114| ||**9,860**|**10,114**| ||**102,368**|**80,889**| ## **4. Income earned from other activities** |Fund raising events
**nvestment income**
**Unrestricted funds**
Bank interest receivable
**Costs of charitable activities by fund type**
**Unrestricted funds**
Charitable activities
Support costs|**2024**
**£**
-|**2023**
**£**
(426)| |---|---|---| ||**-**|**(426)**| ||**2024**
**£**
1,385|**2023**
**£**
1,066| ||**1,385**|**1,066**| ||**2024**
**£**
34,044
47,497|**2023**
**£**
25,627
46,988| ||**81,541**|**72,615**| ## **5. Investment income** ## **6. Costs of charitable activities by fund type** 9 of 15 British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued ## For the year ended 31 December 2024 ## **7. Costs of charitable activities by activity type** |**Support costs**
**Activities**
**undertaken**
**directly**
**£**
**£**
**Support costs**
Charitable activities
47,497
34,044
**Analysis of support costs**
**Charitable activities**
Management
Finance
Computer costs
Depreciation &
amortisation
EBS Admin charges
International Journal of
Immunogenetics
Print, post & stationery
Subscriptions
Telephone
Governance costs|**2024**
**£**
81,541
**2024**
**£**
444
1,359
188
29
32,628
6,500
28
-
309
6,012|**2023**
**£**
72,615
**2023**
**£**
-
1,288
560
10
31,697
6,500
53
580
67
6,233| |---|---|---| ||**47,497**|**46,988**| ## **8. Analysis of support costs** ## **9. Net income/(expenditure) for the year** This is stated after charging/(crediting): ||**2024**|**2023**| |---|---|---| ||**£**|**£**| |Depreciation of owned fixed assets|-|10| |Accountancy fees|1,440|1,440| |(Gain)/Loss on disposal of intangible fixed assets|29|-| 10 of 15 ## British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued ## For the year ended 31 December 2024 ## **10. Particulars of employees** |Employees|**2024**
0|**2023**
0| |---|---|---| ||**0**|**0**| ## **12. Comparative for the Statement of Financial Activities** The comparative year values on the Statement of Financial Activities are for unrestricted funds. ## **13. Intangible fixed assets** |**Cost or valuation**
At 01 January 2024
At 31 December 2024
**Amortisation**
At 01 January 2024
At 31 December 2024
**Net book values**
At 31 December 2024
At 31 December 2023
**Tangible fixed assets**
**Cost or valuation**
At 01 January 2024
Disposals
At 31 December 2024
**Depreciation**
At 01 January 2024
Disposals
At 31 December 2024
**Net book values**
At 31 December 2024
At 31 December 2023|**£**
**Intangible**
**asset 1**
6,668| |---|---| ||**6,668**| ||6,668| ||**6,668**| ||**-**| ||**-**| ||**Plant and**
**machinery**
**£**
380
(380)| ||**-**| ||351
(351)| ||**-**| ||**-**| ||**29**| ## **14. Tangible fixed assets** 11 of 15 British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued For the year ended 31 December 2024 ## **15. Debtors** |**Amounts due within one year:**
Trade debtors
Prepayments and accrued income
**Creditors: amounts falling due within one year**
Trade creditors
Accruals and deferred income|**2024**
**£**
29,284
21|**2023**
**£**
19,380
-| |---|---|---| ||**29,305**|**19,380**| ||**2024**
**£**
11,403
1,440|**2023**
**£**
7,330
1,440| ||**12,843**|**8,770**| ## **16. Creditors: amounts falling due within one year** ## **17. Movement in funds** ## **Unrestricted Funds** |_General_
General
**Unrestricted Funds - Previous year**
_General_
General|**Balance at**
**01/01/2024**
**£**
99,297|**Incoming**
**resources**
**£**
103,753
**103,753**
**Incoming**
**resources**
**£**
81,529
**81,529**|**Outgoing**
**resources**
**£**
(81,541)|**Balance at**
**31/12/2024**
**£**
121,509| |---|---|---|---|---| ||**99,297**||**(81,541)**|**121,509**| ||**Balance at**
**01/01/2023**
**£**
90,383||**Outgoing**
**resources**
**£**
(72,615)|**Balance at**
**31/12/2023**
**£**
99,297| ||**90,383**||**(72,615)**|**99,297**| ## **Purpose of unrestricted Funds** ## General Unrestricted funds are funds that can only be used in accordance with the charitable objects and at the discretion of the trustees. 12 of 15 ## British Society for Histocompatibility and Immunogenetics Notes to the Financial Statements Continued For the year ended 31 December 2024 ## **18. Analysis of net assets between funds** |**Analysis of net assets between funds**|| |---|---| |**Unrestricted funds**
_General_
General
**Previous year**
**Unrestricted funds**
_General_
General|**Intangible**
**fixed assets**
**Tangible**
**fixed assets**
**Net current**
**assets /**
**(liabilities)**
**Net Assets**
**£**
**£**
**£**
**£**
-
-
121,509
121,509| ||**-**
**-**
**121,509**
**121,509**| ||**Intangible**
**fixed assets**
**Tangible**
**fixed assets**
**Net current**
**assets /**
**(liabilities)**
**Net Assets**
**£**
**£**
**£**
**£**
-
29
99,268
99,297| ||**-**
**29**
**99,268**
**99,297**| ## **19. Company limited by guarantee** British Society for Histocompatibility and Immunogenetics is a company limited by guarantee and accordingly does not have a share capital. 13 of 15 ## British Society for Histocompatibility and Immunogenetics Detailed Statement of Financial Activities ## For the year ended 31 December 2024 |**INCOME AND ENDOWMENT**
**Charitable activities**
Advertising (Charitable activities)
Subscriptions (Charitable activities)
Conference (Charitable activities)
Qualifications (Charitable activities)
Other member activities (Other member activities)
Income from charitable activities (Other member
activities)
**Other trading activities**
Fund raising events
**Investments**
Bank interest receivable
**Total incoming resources**
**EXPENDITURE**
**Charitable activities**
Cost of direct charitable activity (Charitable activities)
**SUPPORT COSTS**
**Management**
Management (Charitable activities)
**Finance**
Finance (Charitable activities)
**Computer costs**
Computer costs (Charitable activities)
**Depreciation & amortisation**
Depreciation & amortisation (Charitable activities)
**EBS Admin charges**
EBS Admin charges (Charitable activities)
**International Journal of Immunogenetics**
International Journal of Immunogenetics (Charitable
activities)|**£**
**2024**
18,500
27,030
3,243
43,735
225
9,635
**102,368**
-
**-**
1,385
**1,385**|**£**
**2023**
17,850
26,080
2,800
24,045
-
10,114| |---|---|---| |||**80,889**
(426)| |||**(426)**
1,066| |||**1,066**| ||**103,753**
(34,044)
**(34,044)**
(444)
**(444)**
(1,359)
**(1,359)**
(188)
**(188)**
(29)
**(29)**
(32,628)
**(32,628)**
(6,500)|**81,529**
(25,627)| |||**(25,627)**
-| |||**-**
(1,288)| |||**(1,288)**
(560)| |||**(560)**
(10)| |||**(10)**
(31,697)| |||**(31,697)**
(6,500)| 14 of 15 This page does not form part of the statutory financial statements ## British Society for Histocompatibility and Immunogenetics Detailed Statement of Financial Activities Continued ## For the year ended 31 December 2024 |**Print, post & stationery**
Print, post & stationery (Charitable activities)
**Subscriptions**
Subscriptions (Charitable activities)
**Telephone**
Telephone (Charitable activities)
**Governance costs**
Governance costs (Charitable activities)
**Total resources expended**
**Net Income**|**(6,500)**
(28)
**(28)**
-
**-**
(309)
**(309)**
(6,012)
**(6,012)**|**(6,500)**
(53)| |---|---|---| |||**(53)**
(580)| |||**(580)**
(67)| |||**(67)**
(6,233)| |||**(6,233)**| ||**(81,541)**|**(72,615)**| ||**22,212**|**8,914**| 15 of 15 This page does not form part of the statutory financial statements